Lavipharm S.A Cash Flow Conversion Efficiency

Latest as of December 2022: 0.013x

Lavipharm S.A cash flow conversion efficiency. Based on the latest financial reports, Lavipharm S.A (LAVI) has a cash flow conversion efficiency ratio of 0.013x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€527.00K ≈ $616.12K USD) by net assets (€40.28 Million ≈ $47.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Lavipharm S.A (2014–2024)

Cash flow conversion efficiency of Lavipharm S.A from 2014 to 2024. This chart illustrates how Lavipharm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Lavipharm S.A for real-time trading data and today's change.

Lavipharm S.A Cash Flow Conversion Ratio Explained

Lavipharm S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Lavipharm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lavipharm S.A ranked by their cash flow conversion efficiency. Also see Lavipharm S.A market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
F-SECURE OYJ HE:FSECURE	0.094x
Lionheart Holdings Unit NASDAQ:CUBWU	-0.001x
Lavvi Empreendimentos Imobiliários S.A SA:LAVV3	-0.003x
Nanjing Julong Science & Technology Co Ltd Class A SHE:300644	0.025x
Kung Long Batteries Industrial Co Ltd TW:1537	0.025x
Beijing Jiaman Dress Co. Ltd. A SHE:301276	N/A
Arbonia AG SW:ARBN	0.049x
Valuetronics Holdings Limited F:GJ7	0.021x

Annual Cash Flow Conversion Efficiency for Lavipharm S.A (2014–2024)

The table below shows the annual cash flow conversion efficiency of Lavipharm S.A from 2014 to 2024. Review LAVI cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€52.97 Million ≈ $61.92 Million	€4.64 Million ≈ $5.42 Million	0.088x	+1219.29%
2023-12-31	€42.77 Million ≈ $50.00 Million	€284.00K ≈ $332.03K	0.007x	-92.01%
2022-12-31	€40.28 Million ≈ $47.09 Million	€3.35 Million ≈ $3.91 Million	0.083x	+121.62%
2021-12-31	€-9.94 Million ≈ $-11.62 Million	€3.82 Million ≈ $4.46 Million	-0.384x	-65.91%
2020-12-31	€-12.30 Million ≈ $-14.38 Million	€2.85 Million ≈ $3.33 Million	-0.232x	-15.32%
2019-12-31	€-14.40 Million ≈ $-16.84 Million	€2.89 Million ≈ $3.38 Million	-0.201x	-176.84%
2018-12-31	€-19.53 Million ≈ $-22.83 Million	€1.42 Million ≈ $1.66 Million	-0.073x	+4.54%
2017-12-31	€-19.92 Million ≈ $-23.29 Million	€1.51 Million ≈ $1.77 Million	-0.076x	-299.17%
2016-12-31	€-31.82 Million ≈ $-37.21 Million	€606.00K ≈ $708.48K	-0.019x	-112.96%
2015-12-31	€-64.42 Million ≈ $-75.31 Million	€576.00K ≈ $673.40K	-0.009x	+81.60%
2014-12-31	€-48.96 Million ≈ $-57.24 Million	€2.38 Million ≈ $2.78 Million	-0.049x	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$303.56 Million

€259.65 Million EUR

Market Cap Rank

#14740 Global

#41 in Greece

Share Price

€1.54

Change (1 day)

+0.39%

52-Week Range

€0.80 - €1.70

All Time High

€2.05